Michael Denenberg, MD
Pulmonary Disease · Rock Hill, SCNPI 1538173794
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,203 of the $5,153 with a category attached, or 62.2%. It is spread thinly across 27 manufacturers, the largest accounting for just 22.7%. Reporting peaked in 2019 at $2,627 and has fallen 94.7% since, to $139 in 2025.
Across 183 payments — averaging $28.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$1K
- Astrazeneca UK Limited$1K
- GSK$596
- Insmed, Inc.$365
- Grifols USA, LLC$300
- AstraZeneca$283
- plus $1K from 21 others
Across 1,585 payments — averaging $1979.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$659K
- AstraZeneca$469K
- Sanofi US Services Inc.$321K
- Jazz Pharmaceuticals Inc.$239K
- United Therapeutics Corporation$226K
- Chiesi USA, Inc.$226K
- plus $997K from 21 others
What the payments were for
- Travel & lodging$1,83836%
- Food & beverage$3,20362%
- Education$1122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 13 | $1,172 |
| Astrazeneca UK Limited | 7 | $1,017 |
| GSK | 44 | $596 |
| Insmed, Inc. | 18 | $365 |
| Grifols USA, LLC | 21 | $300 |
| AstraZeneca | 16 | $283 |
| Sanofi | 8 | $259 |
| Boehringer Ingelheim | 10 | $185 |
| Genentech USA, Inc. | 8 | $139 |
| Regeneron Healthcare Solutions, Inc. | 3 | $123 |
| Pulmonx Corporation | 2 | $117 |
| Actelion Pharmaceuticals US, Inc. | 4 | $96 |
| United Therapeutics Corporation | 3 | $86 |
| Mylan Specialty L.p. | 5 | $65 |
| Philips North America LLC | 4 | $62 |
| Inspire Medical Systems, Inc. | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $44 |
| Jazz Pharmaceuticals Inc. | 2 | $42 |
| Advanced Respiratory, Inc | 2 | $25 |
| Shire North American Group Inc | 1 | $23 |
| Olympus America Inc. | 1 | $16 |
| Janssen Scientific Affairs, LLC | 1 | $16 |
| Harmony Biosciences LLC | 1 | $15 |
| Merck | 1 | $15 |
| Resmed Corp | 1 | $14 |
| Circassia Inc. | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$774
- DUPIXENT$125
- Pulmonx Endobronchial Valve EBV$105
How this compares
$5,153 in reported general payments places this provider in the 60th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 290 | $331,113 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 179 | $201,534 |
| OfevNintedanib Esylate | 14 | $164,922 |
| Breo ElliptaFluticasone/Vilanterol | 135 | $106,855 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 65 | $71,856 |
| Spiriva RespimatTiotropium Bromide | 63 | $68,124 |
| SymbicortBudesonide/Formoterol Fumarate | 113 | $53,922 |
| Dupixent PenDupilumab | 11 | $42,053 |
| Wixela InhubFluticasone Propion/Salmeterol | 118 | $33,753 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $27,072 |
| Incruse ElliptaUmeclidinium Bromide | 38 | $23,603 |
| Arnuity ElliptaFluticasone Furoate | 46 | $23,134 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 109 | $23,123 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 439 | $19,073 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $15,474 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $596 | $556,561574 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $185 | $275,592116 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $283 | $262,791303 claims |
| MerckDulera | $15 | $9,04713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Rock Hill
- Arun AdlakhaRock Hill$184K
- Abhijit RavalAnderson$2M
- Richard BoganColumbia$1.1M
- Joseph BosciaSpartanburg$701K
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
- Jake KriegmdColumbia$112K
- Mark MaysonColumbia$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.